Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression

  • Authors: Kenji Niwa, Kokyo Onogi, Yun Wu, Hideki Mori, Yosuke Inoue, Teruhiko Tamaya
  • View Affiliations

  • Published online on: Tuesday, January 1, 2008
  • Pages: 119-122
  • DOI: 10.3892/mmr.1.1.119

Abstract

This study was performed to identify the contribution of cimetidine to chemotherapy for epithelial ovarian carcinoma. Cimetidine was administered two weeks before surgery in combination with platinum-based chemotherapy, and the treatment was continued for two years. Cyclooxygenase-2 (COX-2) expression was also evaluated. The chemotherapy regimens did not affect patient prognosis. The effect of cimetidine was more marked in patients who showed overexpression of COX-2. Platinum-based chemotherapy combined with cimetidine, as a first-line therapy, may improve the prognosis of patients with advanced serous ovarian carcinoma.
Journal Cover

January 2008
Volume 1 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

2012 Impact Factor: 1.17
Ranked #78/121 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Niwa, K., Onogi, K., Wu, Y., Mori, H., Inoue, Y., & Tamaya, T. (2008). Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression. Molecular Medicine Reports, 1(1), 119-122.
MLA
Niwa, Onogi, Wu, Mori, Inoue, and Teruhiko Tamaya. "Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression." Molecular Medicine Reports Molecular Medicine Reports 1.1 (2008): 119-122.
Chicago
Niwa, Onogi, Wu, Mori, Inoue, and Teruhiko Tamaya. "Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression." Molecular Medicine Reports Molecular Medicine Reports 1 no. 1 (2008): 119-122.